EMA401

Research use only, not for human use.

EMA401 (Olodanrigan) is a potent, highly selective angiotensin II type 2 receptor (AT2R) antagonist, inhibits capsaicin responses in cultured neurons of human and rat DRG with IC50 of 10 nM.

EMA401 (Olodanrigan) is a potent, highly selective angiotensin II type 2 receptor (AT2R) antagonist, inhibits capsaicin responses in cultured neurons of human and rat DRG with IC50 of 10 nM; EMA401 is a novel peripherally-restricted analgesic, may act on paracrine/autocrine mechanisms at peripheral nerve terminals, or intracrine mechanisms, to reduce neuropathic pain signalling in AngII/NGF/TRPV1-convergent pathways.Pain Phase 2 Clinical(In Vivo):EMA401 (10 mg/kg; p.o.) results in a significant attenuation of theta power and increase in paw withdrawal latencies (PWL) in rats at day 14 after chronic constriction injury (CCI).

——

EMA401 (10?mg/kg; p.o.) results in a significant attenuation of theta power and increase in paw withdrawal latencies (PWL) in rats at day 14 after chronic constriction injury (CCI).

EMA 401 | EMA-401 | Olodanrigan

GPCR/G Protein

Angiotensin Receptor

angiotensinIIreceptor

Neurological Disease

Pain

1316755-16-4

507.5764

C32H29NO5

>98% (HPLC)

DMSO: ≥ 34 mg/mL

COC1=C(C2=C(CN(C(C2)C(=O)O)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4)C=C1)OCC5=CC=CC=C5

3-Isoquinolinecarboxylic acid, 2-(2,2-diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-, (3S)-

(-20℃)

With Ice Pack

≥ 2 years